VTVTNasdaqPharmaceutical PreparationsFiscal year ends December 31
vTv Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$26.94+0.40 (+1.51%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$6.71 (+33.17%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
vTv Therapeutics Inc. grew revenue 216600.0% to $36.84M over the twelve months to Jun 30, 2026.
Revenue
$36.84M
+216600.0% vs. a year earlier
Operating income
-$9.25M
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $36.84M
- Net income
- -$4.76M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$36.84M+216600.0% YoY
Operating income
-$9.25M
Net income
-$4.76M
Free cash flow
–
Reported periodTrailing twelve months